Study S001785

A Randomized, Double-Blind, Placebo- and Active-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT07801820
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: RECRUITING
Enrollment: 240
Start: 2026-06-23
Primary completion: 2027-03
Lead sponsor: Shanghai Minwei Biotechnology Co., Ltd
Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: DRUG:MWN109 1; DRUG:MWN109 2; DRUG:MWN109 3; DRUG:MWN109 4; DRUG:Placebo; DRUG:Semaglutide Tablets
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 20 Compared to Placebo [Baseline, Week 20]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.